Harvard Bioscience, Inc. (NASDAQ:HBIO) Q4 2022 Earnings Call Transcript

Harvard Bioscience, Inc. (NASDAQ:HBIO) Q4 2022 Earnings Call Transcript March 9, 2023

Operator: Good day, and thank you for standing by. Welcome to the Harvard Bioscience Fourth Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker’s presentation, there will be a question-and-answer session. Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your speaker today, Dave Sirois, Director of SEC Reporting. Please go ahead.

Dave Sirois: Thank you, Shannon and good morning, everyone. Thank you for joining the Harvard Bioscience fourth quarter 2022 earnings conference call. Before we begin, I would like to suggest that you take a moment and download a copy of a presentation that will be referred to during this call. The file is entitled Q4 2022 HBIO Quarterly Earnings Presentation and is located in the Investor Overview, Events and Presentations section of our website. Leading the call today will be Jim Green, Chairman of the Board, President and Chief Executive Officer; and Jennifer Cote, Interim Chief Financial Officer. Before I turn the call over to Jim, I will read our safe harbor statement. In our discussion today, we may make statements that constitute forward-looking statements.

Our actual results and performance may differ materially from what we have projected due to risks and uncertainties including those described in our annual report on Form 10-K for the period ended December 31, 2021, our subsequent quarterly reports on Form 10-Q and our other public filings. Any forward-looking statements, including those related to the company’s future results and activities represent our estimates as of today and should not be relied upon as representing our estimates as of any subsequent day. Also much of today’s call will focus on our non-GAAP quarterly results, which we believe better represents the ongoing economics of the business, reflects how we set and measure our incentive compensation plans and how we manage the business internally.

The difference between our GAAP and non-GAAP results are outlined in the earnings release and today’s presentation. These two documents as well as a replay of this call can be found on our website under Investor Overview Events and Presentations. Additionally any material financial or other statistical information presented on the call, which is not included in our press release and presentation will be archived and available in the Investor Relations section of our website. I will now turn the call over to Jim. Jim please go ahead.

Jim Green: Thank you David. Hello, everyone, and thank you for joining us today. Let me start by saying that despite inflation, currency and the lingering effects of the global supply chain, we kept our heads down and completed the previously disclosed portfolio optimization and related cost reductions. These actions are designed to support our stated goals for revenue growth with 58% to 60% gross margins and EBITDA margins in the high-teens or better. Now let’s go to slide 3 of the presentation to look at highlights for the quarter. Reported revenue for the quarter was $28.4 million, down 14% from a very strong Q4 prior year. Adjusting for a $1 million impact from currency we were down 11%. The majority of the impact was seen in pre-clinical revenues with order demand recovering later in Q4 though not in time for revenue shipments to catch up.

Strong order growth with a substantially improved product portfolio points to a strong start for 2023. Adjusted gross margin recovered to 57% consistent with historical gross margins in spite of the remaining low-margin obsolete products as they wind down. Adjusted operating margin came in at 12%. Going forward, we’ll be reporting adjusted EBITDA, which in Q4 measured 13% of revenue. In the appendix you’ll find the bridge from GAAP measurements to non-GAAP adjusted EBITDA. Adjusted EPS measured $0.04 per share, down from a very strong $0.08 last year. And cash flow from operations measured $2.7 million. Now let’s move to slide 4, take a look at the revenue in the quarter by product family. This slide shows Q4 2022 revenue adjusted to reflect Q4 2021 exchange rates.

Starting with the first row of the table, our cellular molecular technology revenue was roughly flat when adjusted for currency. We had solid growth in Asia Pacific, which was offset by slowness in the Americas. Cell based testing products were up double digits globally. We saw continued rotation out of the low-margin products with revenues from discontinued products decreasing by about $300,000 versus the same quarter last year. We are seeing demand increase going forward, augmented by exciting new products with new consumables and services such as Electroporation for bioproduction. Next, our pre-clinical products were down 19% in constant currency from a historically strong Q4 prior year. Globally telemetry and inhalation revenue shipments were down in Q3 and early in Q4.

Recovering somewhat in the quarter, though, much of the order improvement came later in the quarter. The China lockdown further delayed shipments, with strong order demand recovering later in the quarter as lockdowns eased. Overall, order demand recovery later in the quarter didn’t help Q4 much, but strong order growth with a solid book-to-bill ratio point to a strong start for 2023. The strong U.S. dollar compared to the euro and British pound drove a currency impact of the $1 million, I spoke of earlier. Now let’s move to slide 5, so I can tell you about some of the exciting new product launches in the quarter. Before I start, let me take a minute to explain a little bit about this slide. Over the last three years, we’ve optimized our product offerings to critical areas of the drug and therapy continuum.

With cellular molecular technology products focusing on enabling research and discovery of new compounds by both biopharma companies and top academic research universities. And now more recently, we’re also offering a bridge to bioproduction where Electroporation or electrofusion is a widely used method to create the new therapy, drug or vaccine. Our preclinical systems primarily offer biotech, pharma, CRO and large academics the ability to measure and wirelessly collect critical physiologic behavioral information from animal models. This data has been utilized for longitudinal studies and for the safety and regulatory filings required prior to clinical human clinical use. Our enterprise software provides efficient access to the large data pools collected during preclinical testing for data reduction, post and report generation and also for future AI-related processing as we see coming in the future.

Starting with Cellular Molecular Technologies, in Q4 we received a large order from a top pharma company for our BTX Electroporation system configured for bio-production. This order began significant shipments in Q1 of 2023 and is expected to quickly ramp to $1 million annually, primarily driven by consumption of our unique Flatpack Reaction Chambers and augmented by expanded services. We’re excited about this emerging value proposition for the BTX system, in bio-production, which is often used today in pharmaceutical research and development to create the initial strength of therapeutics and vaccines. BTX Electroporation has the potential to provide substantial ongoing stream of Flatpack and other consumable revenue that benefits from production quantities in addition to those historically required in research and discovery.

Second, we introduced, the new U7500 our Premium Spectrophotometer building on our well-known ultra-spec name. This system replaces three existing models, and is designed to better penetrate pharma and CRO companies and top academic sites and started shipping late in Q4. Lastly, continuing to drive market leadership in preclinical, wireless continuous monitoring we launched our “Exclusive” continuous monitoring Glucose Implant. This new implant allows for continuous monitoring of glucose levels and avoids the cost, inconvenience and variability inherent in periodic manual blood draws for sampling. Glucose monitoring is expected to be an incremental growth driver in academic labs and government labs and pharma companies in the pursuit of solutions for the ever-growing problems of obesity and diabetes.

This new line of implants began shipping late in Q4 and will augment new growth of our consumables and services in 2023 and beyond. Now I’ll turn the call over to Jennifer Cote, our interim CFO, for a quick look at key financials. Jen?

Jennifer Cote: Thank you, Jim. I’m pleased to be able to share our financial results in greater detail. If you can please refer to slide 7, as a reminder my discussion will focus on adjusted results for P&L performance which aligns with measurements we use to internally manage the business. Jim has already taken you through our revenue performance, and I will take you through additional details on our expenses, balance sheet and cash flows. Q4 adjusted gross margin was 57.2%, as discussed earlier, this was consistent with the full year 2021 adjusted gross margin but was 2.4 percentage points below that of last Q4, 2021. Q4 2021 was a near record quarter for revenue and this drove favorable absorption of fixed overhead costs.

Our gross margin for Q4, 2022, was also impacted by increases in certain components costs. In general, our gross margin will fluctuate from period to period based on revenue mix and volume inflation, impact to supply chain among other factors. We initiated the discontinuation of non-strategic products in Q3 and also implemented pricing updates during Q4. We will enter Q1 of 2023 with lower labor and overhead costs, as the headcount reductions related to our portfolio rationalization are realized. With the implementation of these improvements, together with our pricing increases, we expect to see initial margin improvement in Q1 and to achieve the full benefit of these changes in Q2. Now, moving to operating margin. Q4 adjusted operating margin was $3.4 million or 11.9% compared to $5.3 million or 16% in Q4, 2021.

The decrease was primarily driven by lower revenue and as a result, lower gross margin, partially offset by lower operating expenses in Q4. We continue to work diligently to optimize our cost structure across our global functions. Planned restructuring is largely behind us as we exit 2022, although, we will continue to look for opportunities to improve the operating effectiveness of our company going forward. We do expect an increase in capital expenditures in 2023, as we invest in the consolidation of certain business tools and also invest in tooling and capital equipment related to new products. As we enter 2023, we will start to report on adjusted EBITDA, as Jim mentioned, in replacement of operating income and margin. The primary difference for Harvard Bioscience is depreciation on our fixed assets, which is approximately $300,000 each quarter and we believe this change aligns more closely with our focus on cash flow improvements and is consistent with the presentation of other comparable companies.

Interest expense was $900,000 in Q4 2022 as compared to $400,000 in Q4 of 2021. We executed an interest rate swap during Q1 of 2023 to fix the majority of the interest on our floating rate bank debt and this mitigates further expense growth in 2023. Now, turning my attention to cash flow. As Jim mentioned, cash flow provided by operations was $2.7 million in Q4 of fiscal 2022 compared to $100,000 in last Q4. Primary drivers for this change related to accruals for variable compensation. Cash provided by operations for the full year was $1.2 million, consistent with 2021, despite $4 million of cash payments related to the final resolution of SEDAR litigation which we put behind us early last year. Over the course of the year, we saw strong improvements in our days sales outstanding and reduced our accounts receivable balance by $4.8 million over the course of 2022.

Inventory remains relatively flat, despite the headwinds of higher component costs and spot purchases, to secure raw materials needed to produce our products. We expect to make meaningful progress against our days’ inventory on hand metric in 2023. While our net debt is slightly higher at the end of 2022, we did reduce our outstanding debt by $1.8 million over the course of the year. This will be a focus and a strategic priority for us in 2023, and we are targeting solid reductions in our outstanding debt. Jim will cover this in the next section, as he discusses 2023 guidance. Back to you, Jim.

Jim Green: Thanks, Jen. Now, moving to our summary on slide nine and a look at what we see for the year 2023. With the market headwinds of 2022 behind us, our lean cost structure and our exciting new product portfolio in hand, we expect a strong 2023 for Harvard Bioscience. We expect reported revenue growth in the low to mid-single-digit range, inclusive of approximately 4 percentage points of discontinued product revenue. We also expect improved gross margins with significant expansion in adjusted EBITDA margins. With our expanded EBITDA, combined with improved working capital cash flow, we plan to significantly pay down our debt. We target reducing our debt leverage to the 2x level by the end of 2023. Thank you. Now, I’ll turn the call back over to the operator and open the line for questions. Thanks.

See also 15 Largest Commercial Printing Companies in the World and 12 High Growth Forever Dividend Stocks.

Q&A Session

Operator: Thank you. Our first question comes from the line of Bruce Jackson with Benchmark Company. Your line is now open.

Jim Green: Hi, Bruce.

Bruce Jackson: Hi, good morning. Good morning and thank you for taking my question. So you mentioned that, we would potentially be seeing some gross margin improvement during 2023. I was wondering, if maybe you could give us an idea of the cadence on that margin improvement. So is going to continue to rise off the fourth quarter number? And where do you think it could get to by the end of the year?

Jim Green: Thanks, Bruce. That’s a great question. We expect to see gross margin improve almost immediately. We will see €“ so we would expect to see the margin move into the 58% to 60% region, and I mean even in early in the year, and then improving through the year especially as we get to late in the year with higher volumes, certainly, I would expect to be bouncing up against 60% or some are right in that area.

Bruce Jackson: Okay. And then the other question, I had is on the non-cash expenses, when we’re looking at the new EBITDA number. Will the stock comp or the amortization numbers change meaningfully during 2023 compared to 2022?

Jim Green: I don’t think so. I think, they’ll probably remain pretty stable. So there you already see those adjustments made in what we’ve always used for adjusted operating margin. What you’ll see by moving to EBITDA is really also adding the depreciation and for us depreciation is not a great big number. We’re not highly capital intensive, but we do think it gives us more of a pro-forma view of basically the cash generation of the company. And that’s where we’re really focusing this year is driving up EBITDA, reducing our multiple on our leverage ratio, paying down the debt, and really positioning, getting this business back into great shape, just like we started to do back, when I first joined here, but now that we’ve completely changed the structure and the cost of the business, and really made these changes have a much stronger portfolio this is going to improve throughout the year.

And like I said, even starting in Q1, you’re going to €“ I believe you’re going to see measurable improvement in the overall business. There is going to be some rotation out of revenue this revenue that we’re working out of the things that we’ve obsoleted. And we project that to be somewhere around $5 million, or four percentage points. Much of that is going to rotate out in Q1. And then as we get into Q2 and forward, we certainly see expansion of our core revenues offsetting that number early in the year, and then driving the overall growth as we get to more like Q3, Q4. But all through the year, you’ll see a much better operating leverage on this business.

Bruce Jackson: Okay. Okay. Then last question for me is on China. Sometimes, historically, the revenue number has shown some sensitivity to market conditions in China. What are you seeing right now? And what do you anticipate for 2023?

Jim Green: China is €“ we see that this as a major growth driver for our business and we see it we’re driving across the spectrum of our product lines both in €“ we see growth coming very nicely on the CMT side, and on the pre-clinical. We did with the shutdowns that happened last year it caused some fluctuation and delays in ordering at times, and then impacts on shipment and shipment revenues. But there was probably some buildup in late in Q4 with the book-to-bill really moving so we couldn’t ship things fast enough. But the demand line the demand stream really has dramatically improved in China. They’ve opened up. There’s also a lot more investment in China now in advanced research for discovery. We’re seeing that driving our outlook for China.

We see significant opportunity growing also on the preclinical side, because that’s an area that the Chinese really want to grow that area, both in research and then in the ability to actually produce these new drugs and therapies. So yes, China is definitely going to be a big growth driver for us in 2023.

Bruce Jackson: Thank you.

Jim Green: Thanks, Bruce.

Operator: Thank you. Our next question comes from Harrison Schrage with KeyBanc. Your line is open.

Jim Green: Hi, Harrison.

Harrison Schrage: Hey, Jim. Hi. First question for me is just on the guide. So low to mid single-digits was about 4% of the portfolio optimization. Would you say that that high single-digit to low double-digit range that that kind of implies on the base business is a good way to think about it going forward in the longer term?

Jim Green: I do. And that’s really consistent with what we wanted — what I wanted to be able to underpin for targets to start with. And again, like I said, we’ll see a little rotation out with the $5 million coming out in Q1 and maybe some in Q2. But that gets replaced almost as that comes out it replaces with the new growth. And then, new growth as you know is it’s much, much better mix of business. So yeah, I think you’ve kind of hit that right kind of high single-digits on a reported basis maybe it’s close to 10% and then that would be on the core business. We done on a reported basis kind of in that I don’t know maybe it’s flat or a little better than flat to 5-ish percent maybe a little better. And I’ll give better updates as we get a little further into the year and I’m able to give more — better visibility into further points into the year as those funnels develop in the pipeline.

Harrison Schrage: Got it. That’s helpful. And then on the portfolio optimization and new products that you’re rolling out. I guess could you kind of talk to strategically how you’re thinking about the different end markets that you’re going to be catering to and the new business and new portfolio compared to the old portfolio maybe in terms of is it more biopharma compared to academic government? And what are you kind of thinking there?

Jim Green: Yeah. I think of them in many ways is somewhat independent activities, but the focus is in key areas. So our technologies in discovery like electroporation and the cell-based testing those sell through are and report through our molecular and cellular molecular side, those that we expect nice expansion there. We know what all is happening in the use of electroporation, electrofusion for creation of these new exciting new drugs and large molecule therapies and vaccines. So that’s going to drive growth into academic research and discovery. And the new introduction of the ability for us to provide bio-production — bridge to bio-production especially where they used us to create the initial compound that’s a natural for us to be able to expand.

And for us it’s new. It’s a lot of white space and it’s a place that we’re putting the effort in and the time to make sure that that drives growth for our business. You’ll also see that there’s a much more focus on us identifying and showing the annuity-based growth in the business. It turns out we haven’t in the past in many ways even had much of the tools to be able to properly report it. But some of our product lines in a product line like AAA or our electroporation I mean those revenue lines half of that is likely we see as consumables and services. So we’re expanding the consumables piece, the new products that we’re introducing are designed primarily to go in as a system that has the pull-through of consumables and new services. We’re expanding our service offerings a lot of our products that are used — if they’re used in bio-production we can go out and offer and help the pharmaceutical company or the biotech get through the GMP process that had to be qualified so they can produce product with our technology.

And then on the pre-clinical side, you have to have GLP compliance to be able to collect the data for submitting your regulatory submissions. We do that also. So expanding the services to these companies once they buy our equipment — in the past we often we’re seeing it just selling a piece of capital equipment and that was the end of it. That’s no longer the strategy here and we’re seeing this change. So the systems go in, we now are offering and expect to see much more growth on the consumable side. We also with new expanded service offerings, we’re involved with going out now and offering the calibration and the installation services and the support services going forward once they use our equipment. So again, I’d highlight maybe three or four areas where we see real opportunity to grow and much of it here in the short term not long-term — not a long time wait for it.

I would also say though that the long-term value proposition, we see access to the large data pools that are collected with our enterprise software solutions and our Ponemah software. That’s what’s been used for the majority of pharmaceutical companies CROs for creating, for collecting all the data during the pre-clinical phases. And we all know that there’s going to be a hard push to use historical data and longitudinal data to be able to submit and show that new drugs can leverage on testing that’s maybe already been done in a line. They’ll still have to go through the final. We believe they still have to go through all the final talks and safety pharmacology tests, which there, of course, that’s a big part of our business and very stable.

But the ability for us to offer access to large data pools that were collected, we know that some of the new advanced data processing is coming AI-based applications and getting access to that data is going to be — that will be another area of expansion in the business. That’s probably a little bit further down the road. But we have to — we are able to here. So can’t invest in everything at the same time, but picking out the key ones bio-production I think advancements that we see coming in moving to organoids. That’s an area where we’re very well-positioned. We already have the technology that where you put the organ on the chip, we already build those kinds of chips. So — again we’ve got three or four very interesting areas and I’m looking forward to my next €“ on the roadshow where I can really show the shareholders where these investments are going and show that there is an opportunity to dramatically grow this business and improve it.

Harrison Schrage: Got it. Super helpful. Thanks, Jim.

Jim Green: Right. Thank you, Harrison.

Operator: Thank you. Our next question comes from the line of Christopher Sakai with Singular Research. Your line is now open.

Jim Green: Hi, Christopher.